Neurology Market: A BCC Research Overview

Report Scope

This report includes a market analysis of the therapeutics used to treat neurological conditions. The study outlines the market potential for neurology medications for both now and in the future. It also provides a thorough examination of the market’s drivers, constraints, and pipeline medications, as well as the competitive landscape, laws, epidemiology of neurological disorders, mergers and acquisitions. Market forecasts through 2029 are also covered in the report.

The report breaks down neurology market shares according to various disease indications. Parkinson’s disease, Alzheimer’s disease, psychotic disorder, epileptic disorder, autism disorder, multiple sclerosis, brain tumor, and other diseases are the neurological disorders that make up the market segmentation. Therapeutics and regional analysis are covered in each disease segment.

Anti-Parkinson’s medications are covered in the Parkinson’s disease market. The market is divided into different drug classes such as dopaminergic, enzyme inhibitors, dopamine agonists and other anti-Parkinson’s drugs based on drug class. Anti-Alzheimer medications are part of the Alzheimer’s disease market, which is divided into segments according to respective mechanisms of action. The market is divided into two segments based on drug class: NMDA antagonists and AChE inhibitors. Antipsychotic medications are part of the market for psychotic diseases. The market is divided into different drug classes, including D2 partial agonists, D2/5HT2A antagonists, and D2 antagonists.

Anti-epileptic medications are included in the market for epileptic diseases. The market is divided into three segments based on drug class: first-generation, second-generation and third-generation. Autism spectrum disorder drugs are included in the market. Based on information on labels, the market is divided into drug categories: off-label pharmaceuticals and pharmaceuticals with an ASD label. Brain tumor treatments are included in the market for brain tumors. The market is divided into different types of therapy, such as targeted therapy and chemotherapy.

In order to provide an in-depth understanding of the market, profiles of market participants, competitive landscape, key competitors and respective market share are also part of this report. By geographical region, the market in this report is divided into four regions: North America, Europe, Asia-Pacific, and Rest of the World (RoW). For market estimates, data has been provided for 2023 as the base year, with forecasts for 2024 through 2029.

Report Includes

• 52 data tables and 59 additional tables
• Analyses of the global market trends for neurology therapeutics, with market revenue data (sales figures) for 2022, estimates for 2023, forecasts for 2024, and projected CAGRs through 2029
• Estimates of the market size and revenue growth prospects, along with a market share analysis by type of disorder, drug classification, mechanism of action, label information, end user and region
• Facts and figures pertaining to key market dynamics, technology advances, pipeline drugs, regulations, and the impact of macroeconomic factors
• Insights derived from the Porter’s Five Forces model, as well as global supply chain and PESTLE analyses
• Pipeline analysis covering ongoing clinical trials and promising forthcoming neuroscience therapies in late stage
• Discussion of therapeutics used for treatment of neurological disorders, along with coverage of novel pipeline drugs, patent expiries of blockbuster drugs and new drug approvals
• A patent analysis, including key granted and published patents
• Analysis of the industry structure, including companies’ market shares and rankings, strategic alliances, M&A activity and a venture funding outlook
• Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, and the ESG scores and practices of leading companies
• Company profiles of major players within the industry, including F. Hoffmann-La Roche Ltd., Novartis AG, UCB S.A, and Otsuka Holdings Co. Ltd.

Companies Mentioned

Abbvie Inc.
Alpha Cognition
Biogen
Boehringer Ingelheim International Gmbh
Bristol-myers Squibb Co.
Eisai Co. Ltd.
F. Hoffmann-la Roche Ltd.
H. Lundbeck A/S
Lilly
Merck & Co. Inc.
Novartis Ag
Otsuka Holdings Co. Ltd.
Sanofi
Teva Pharmaceutical Industries Ltd.
Ucb S.A.